MedTrace Logo

Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms

NCT05795816 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-03-10

No results posted yet for this study

Summary

This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Testofen (a specialised extract of Trigonella foenum-graecum (Fenugreek) seed) compared to placebo on post COVID-19 symptoms in otherwise healthy participants 18 years and over.

Conditions

  • Long Covid19

Interventions

DRUG

Testofen

Twice daily dose of 1 capsule (300mg per capsule Testofen)

DRUG

Microcrystalline cellulose

Twice daily dose of 1 capsule

Sponsors & Collaborators

  • RDC Clinical Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Amanda Rao, PhD · RDC Clinical Pty Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-25
Primary Completion
2025-01-30
Completion
2025-01-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05795816 on ClinicalTrials.gov